Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth
Sign Up to like & getrecommendations! Published in 2019 at "Gene Therapy"
DOI: 10.1038/s41434-019-0071-x
Abstract: For patients with metastatic prostate cancer, the 5-year survival rate of 31% points to a need for novel therapies and improvement of existing modalities. We propose that p53 gene therapy and chemotherapy, when combined, will… read more here.
Keywords: prostate carcinoma; gene therapy; adrgd pgp53; gene ... See more keywords